Moderna Inc

NASDAQ: MRNA
$107.89
+$3.43 (+3.3%)
Closing price April 23, 2024
Moderna Inc is a pioneering biotechnology firm based in Cambridge, Massachusetts, known for its innovative use of messenger RNA (mRNA) to develop vaccines and therapeutics. The company has made significant strides in addressing infectious diseases, including COVID-19, influenza, and more, as well as tackling challenges in immuno-oncology, rare diseases, autoimmune disorders, and cardiovascular diseases. Moderna's portfolio includes both respiratory and latent vaccines, public health vaccines, and treatments for infectious diseases. Additionally, it focuses on systemic secreted, cell surface therapeutics, cancer vaccines, and inhaled pulmonary therapeutics, supported by strategic alliances with global pharmaceutical leaders and research organizations.
24/7 Wall St. has compiled a list of a few of the biggest movers along why they are moving, a recent trading history and what the consensus estimate is from analysts.
Monday's top analyst upgrades and downgrades included AMC Entertainment, Bed Bath & Beyond, Halliburton, Intuit, Moderna, Nikola, Phillips 66, Stitch Fix and Virgin Galactic.
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Wednesday's top analyst calls included American Express, Apple, Baidu, CarMax, Chewy, Lululemon Athletica, Micron Technology, Moderna, Slack, Walt Disney and Zoom Video Communications.
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Moderna shares continued to run higher on Monday after the company announced an update for the primary efficacy analysis for its late-stage coronavirus vaccine trial.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Monday's top analyst upgrades and downgrades included Darden Restaurants, Foot Locker, Gap, Kellogg, Moderna, Philip Morris International, Prologis, Rockwell Automation and Texas Roadhouse.
Tuesday's top analyst upgrades and downgrades included AECOM, BBVA, Cheniere Energy, Chevron, DraftKings, General Motors, Moderna, Novavax, Palo Alto Networks and Penn National Gaming.
Moderna reported a 95.4% effectiveness rate for its COVID-19 vaccine. This is the second vaccine to hit more than 90% efficacy in the past week.
Wednesday's top analyst upgrades and downgrades included AIG, CrowdStrike, Datadog, Devon Energy, eGain, Lyft, Moderna, Occidental Petroleum, Peloton Interactive and Yelp.
When Moderna reported its most recent quarterly results before the markets opened on Thursday, the earnings (or loss in this case) were not the most important feature of the report.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.